Nosocomial urinary tract infections


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Texto integral

Acesso é fechado

Sobre autores

S. Yakovlev

M. Suvorova

Bibliografia

  1. Агеевец В.А., Партина И.В., Лисицына Е.С. и др. Чувствительность грамотрицательных бактерий, продуцентов карбапенемаз, к антибиотикам различных групп. Антибиотики и химиотерапия. 2013;58(3-4):3-6.
  2. Дворецкий Л.И., Яковлев С.В. Пожилой больной и инфекция: Руководство для врачей. М.: ГЭОТАР-Медиа, 2008. 368 с.
  3. Национальная концепция профилактики инфекций, связанных с оказанием медицинской помощи, и информационный материал по ее положениям / В.И. Покровский, В.Г. Акимкин, Н.И. Брико и др. Н. Новгород: Ремедиум Приволжье, 2012. 84 с.
  4. Сидоренко С.В., Яковлев С.В. Инфекции в интенсивной терапии. 2-е изд., перараб. и доп. М.: Бионика, 2003. 208 с.
  5. Стратегия и тактика применения антимикробных средств в лечебных учреждениях России: Российские национальные рекомендации / Под ред. В.С. Савельева, Б.Р. Гельфанда, С.В. Яковлева. М.: Компания БОРГЕС, 2012. 92 с. (текст доступен на сайте www.antimicrob.net).
  6. Яковлев С.В., Суворова М.П., Колендо С.Е. и др. Клиническая эффективность антимикробного препарата фурамаг при больничных инфекциях МВП. Терапевтический архив. 2014;10:65-72.
  7. Яковлев С.В., Суворова М.П. Обоснование антибактериальной терапии нозокомиальных инфекций, вызванных полирезистентными микроорганизмами. Клиническая фармакология и терапия. 2011;20(2):1-10.
  8. Яковлев С.В., Белобородов В.Б., Суворова М.П. и др. Многоцентровое исследование распространенности и клинического значения инфекций, связанных с оказанием медицинской помощи в скоропомощных многопрофильных стационарах России / Научные материалы Всероссийской научно-практической конференции специалистов по контролю инфекций, связанных с оказанием медицинской помощи, с международным участием. МедиАль, 2014;3(13):140.
  9. Яковлев С.В., Белобородов В.Б., Сидоренко С.В. и др. Анализ адекватности стартовых эмпирических режимов антибактериальной терапии при тяжелых нозокомиальных инфекциях (исследование АСЭТ). Клиническая фармакология и терапия. 2006;15(2):14-20.
  10. Ahmed N.H., Hussain T., Biswal I. Comparison of etiological agents and resistance patterns of the pathogens causing community acquired and hospital acquired urinary tract infections. J. Global Infect. Dis. 2014;6:135-136.
  11. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 1992;20(6): 864-874.
  12. Bjerklund-Johansen T.E., Cek M., Naber K. et al. PEP and PEAP study investigators. Prevalence of hospital-acquired urinary tract infections in urology departments. Eur. Urol. 2007;51(4):1100-1111.
  13. Bouza E., San Juan R., Munoz P. et al. A European perspective on nosocomial urinary tract infections II. Report on incidence, clinical characteristics and outcome (ESGNI-004 study): Eur. Study Group on Nosocomial Infection. Clin. Microbiol. Infect. 2001;7(10):532-542.
  14. Burton D., Edwards J., Srinivasan A. et al. Trends in catheter-associated urinary tract infection in adult intensive care units - United States, 19902007. Infect. Control. Hosp. Epidemiol. 2011;32:748-756.
  15. Chang R., Greene M.T., Chenoweth C.E. et al. Epidemiology of hospital-acquired urinary tract-related bloodstream infection in a university hospital. Infect. Control. Hosp. Epidemiol. 2011;32:1127-1129.
  16. Chenoweth C.E., Saint S. Urinary tract infections. Infect. Dis. Clin. N. Am. 2011;25(1):103-115.
  17. Chenoweth C.E. Urinary tract Infections. In: Bennett & Brachman’s hospital infections / Ed. Jarvis W.R. 6-th edition. Lippincott Williams & Wilkins, a Wolters Kluwer business, Philadelphia, USA, 2014:476-484.
  18. Chitins A., Edwards J., Ricks P. et al. Device-associated infection rates, device utilization, and antimicrobial resistance in long-term acute care hospitals reporting to the National Healthcare Safety Network, 2010. Infect. Control. Hosp. Epidemiol. 2012;33:933-1000.
  19. Clark N.M., Hershberger E., Zervos M.J., Lynch J.P. Antimicrobial resistance among gram-positive organisms in the intensive care unit. Curr. Opin. Crit. Care. 2003;9:403-412.
  20. De La Rosa G.D., Valencia M.L., Arango C.M. et al. Toward an operative diagnosis in sepsis: a latent class approach. BMC Infectious Diseases. 2008;8(18):1-9.
  21. Dellinger P.R., Levy M.M., Rhodes A. et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit. Care Med. 2013;41(2):580-637.
  22. Filho L.S., Eagye K.J., Kuti J.L., Nicolau D.P. Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy. Clin. Microbiol. Infect. 2007;13:579-585.
  23. Fortin E., Rocher I., Frenette C. et al. Healthcare-associated bloodstream infections secondary to a urinary focus. Infect. Control. Hosp. Epidemiol. 2012;33:456-462.
  24. Ghadiri H., Vaez H., Khosravi S. et al. The antibiotic resistance profiles of bacterial strains isolated from patients with hospital-acquired bloodstream and urinary tract infections. Crit. Care Res. Pract. 2012:1-6.
  25. Grabe M., Bjerklund-Johansen T.E., Botto H. et al. EAU Guidelines on urological infections, 2012.
  26. Green M.T., Chang R., Kuhn L. et al. Predictors of hospital-acquired urinary tract-related bloodstream infection. Infect. Control. Hosp. Epidemiol. 2012;33:1001-1007.
  27. Hidron A.I., Edwards J.R., Patel J. et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006 2007. Infect. Control. Hosp. Epidemiol. 2008;29(11):996-1011.
  28. Hooton T.M., Bradley S.F., Cardenas D.D. et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society ofAmerica. Clin. Infect. Dis. 2010;50:625-663.
  29. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of healthcare-associated infection and criteria for specific types of infections in acute care settings. Amer. J.Infect. Control. 2008;36(5):309-332.
  30. Horcajada J.P., Shaw E., Padilla B. et al. Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicenter cohort study in the era of antimicrobial resisatnce. Clin. Microbiol. Infect. 2013;19:962-968.
  31. Klevens R.M., Edwards J.R., Richards C.L. et al. Estimating health care-associated infections and death in U.S. hospitals, 2002. Public Health Rep. 2007;122(2):160-166.
  32. Kumarasamy K.K., Toleman M.A., Walsh T.R. et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010; 10(9): 597-602.
  33. Lark R.I., Grenoweth C.E., Saint S. et al. Four year prospective evaluation of nosocomial bacteremia: epidemiology, microbiology and patient outcome. Diagd. Microbiol. Infect. Dis. 2000;38:131-140.
  34. Livermore D. Current Epidemiology and growing resistance of Gramnegative pathogens. Korean J. Intern. Med. 2012;27:128-142.
  35. Livermore D.M., Warner M., Mushtaq S. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int. J. Antimicrob. Agents. 2011;37(5):415-419.
  36. Lo E., Nicolle L., Classen D. et al. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals. Infect. Contr. Hosp. Epidemiol. 2008;29(Suppl 1):S.41-49.
  37. Magill S.S., Edwards J.R., Bamberg W. et al. Multistate Point-Prevalence Survey of Healthcare-Associated Infections. N. Engl. J. Med. 2014;370:1198-1208.
  38. Moise-Broder PA., Sakoulas G., Eliopoulos G.M. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 2004;38: 1700-1705.
  39. Neoh H., Hori S., Komatsu M. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann. Clin. Microbiol. Antimicrob. 2007;6:13-22.
  40. Nordmann P., Dortet L., Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm. Trends Mol. Med. 2012;18(5): 263-272.
  41. Nordmann P., Gniadkowski M., Giske C.G. et al. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin. Microbiol. Infect. 2012;18:432-438.
  42. Nordmann P., Poirel L. Strategies for identification of carbapenemase-producing Enterobacteriaceae. J.Antimicrob. Chemother 2013;68:487-489.
  43. Platt R., Polk B.F., Murdock B. et al. Risk factors for nosocomial urinary tract infection. Am. J. Epidemiol. 1986;124:977-985.
  44. Poisson N., Johston S.C., Josephson S.A. Urinary tract infections complicating stroke. Mechanisms, consequences, and possible solutions. Stroke. 2010;41:E180-184.
  45. Pollack M. Pseudomonas aeruginosa. In: Principles and Practice of Infectious Diseases / Ed. by G.L. Mandell, J.E. Bennett, R. Dolin. 4th ed. London: Churchill Livingstone, 1995. P. 1980-2003.
  46. Rybak M.J., Lomaestro B.M., Rotschafer J.C. et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. 2009;49(3):325-327.
  47. Sader H.S., Fritsche T.R., Jones R.N. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob. Agents Chemother. 2006;50(7):2330-2336.
  48. Saint S. Chenoweth C.E. Biofilms and catheter-associated urinary tract infections. Infect. Dis. Clin. N. Am. 2003;17:411-432.
  49. Saint S., Meddings J.A., Calfee D. et al. Catheter-associated urinary tract infection and the medicare rule changes. Ann. Intern. Med. 2009;150: 877-884.
  50. Stevens D.L. The role of vancomycin in the treatment paradigm. Clin. Infect. Dis. 2006;42:51-57.
  51. Tambyah P.A., Maki D.G. Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. Arch. Intern. Med. 2000;160:678-682.
  52. Tenke P., Kovacs B., Bjerklund Johansen T.E. et al. European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Intern. J. Antimicrob. Agents. 2008;31:68-78.
  53. Tissot E., Limat S., Gornette C. et al. Risk factors for catheter-associated bacteriuria in a medical intensive care unit. Eur. J. Clin. Microb. Inf. Dis. 2001;20:260-262.
  54. Tsakris A., Poulou P., Pournaras S. et al. A simple phenotypic method for the differentiation of metallo-beta-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. J. Antimicrob. Chemother. 2010;65:1664-1671.
  55. Van Nieuwkoop C., Bonten T.N, Van’t Wout J.W. et al. Risk factors for bacteremia with uropathogen not cultured from urine in adults with febrile urinary tract infection. Clin. Infect. Dis.2010;50:E.69-72.
  56. Vincent J.-L., Rello J., Marshall J. et al. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA. 2009;302(21):2323-2329.
  57. Walsh T.R. Emerging carbapenemases: a global perspective. Int. J. Antimicrob. Agents. 2010;36(Suppl 3):S.8-14.
  58. Warren J.W., Damron D., Tanney J.H. Fever, bacteremia, and death as complications of bacteriuria in women with long-term urethral catheters. J. Infect. Dis. 1987;155:1151-1158.
  59. Yakovlev S.V., Beloborodov V.B., Suvorova M.P. et al. Multicentre Study of the Prevalence and Clinical Value of Hospital-Acquired Infections in Emergency Hospitals of Russia. Abstract K-574. 54th ICAAC, Sept 5-9, 2014, USA, Washington, DC
  60. Yigit H., Queenan A.M., Rasheed J.K. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2. Antimicrob. Agents. Chemother. 2003;47(12):3881-3889

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2016

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies